Bioceres Crop Solutions Corp. (BIOX)
| Market Cap | 27.23M -90.1% |
| Revenue (ttm) | 255.21M -33.4% |
| Net Income | -247.25M |
| EPS | -3.88 |
| Shares Out | 63.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,741 |
| Open | 0.4433 |
| Previous Close | 0.4494 |
| Day's Range | 0.4268 - 0.4765 |
| 52-Week Range | 0.34715 - 5.1750 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 4.33 (+909.32%) |
| Earnings Date | May 11, 2026 |
About BIOX
Bioceres Crop Solutions Corp., together with its subsidiaries, develops and commercializes crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, comm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BIOX stock is "Buy." The 12-month stock price target is $4.33, which is an increase of 909.32% from the latest price.
News
Bioceres Crop Solutions Earnings Call Transcript: Q3 2026
Fiscal Q3 2026 saw a 23% revenue decline and a $10 million net loss, driven by lower gross profit and the impact of the ProFarm foreclosure, which resulted in a $179 million non-cash loss. Management is focused on liquidity, legal disputes, and streamlining operations.
Bioceres reports Q3 operating profit $4.3M vs. ($4.3M) last year
Reports Q3 revenue $39.4M, one estimate $54.5M. Mr. Federico Trucco, Bioceres (BIOX)’ Chief Executive Officer, commented: “This quarter reflects a period of transition and operational refocusing for t...
Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricul...
CORRECTING and REPLACING Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time
ROSARIO, Argentina--(BUSINESS WIRE)--The dial-in details of release dated May 4, 2026 have been revised. The US Toll Free dial-in number should read 1-833-461-5787; the International dial-in numbers l...
Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a leader in the development and commercialization of productivity solutions designed to...
A Message from Our Chief Executive Officer
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX): Dear Fellow Shareholders, This communication accompanies the filing of our Form 6-K for the second quarter of fiscal ...
Bioceres price target lowered to $2 from $2.25 at Canaccord
Canaccord analyst Austin Moeller lowered the firm’s price target on Bioceres (BIOX) to $2 from $2.25 and keeps a Hold rating on the shares. On December 18, New York’s Supreme…
Bioceres announces appointment of Ezequiel Simmermacher as CFO
Bioceres (BIOX) Crop Solutions announced the appointment of its Chief Financial Officer and changes to the composition of the board of directors of the company. Ezequiel Simmermacher is being appointe...
Bioceres price target lowered to $2.25 from $2.50 at Canaccord
Canaccord lowered the firm’s price target on Bioceres (BIOX) to $2.25 from $2.50 and keeps a Hold rating on the shares. The firm reported lower Q1 revenues and adjusted EBITDA.
Bioceres Crop Solutions Earnings Call Transcript: Q1 2026
Revenue fell 17% year-over-year to $77.5 million, but gross margin expanded to 47% and adjusted EBITDA rose 61% due to cost reductions. Segment margins improved, though seed and crop protection revenues declined. Net debt remained stable amid ongoing debt dispute.
Bioceres Crop Solutions Reports Fiscal First Quarter 2026 Financial and Operational Results
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricul...
Bioceres Crop Solutions to Host Fiscal First Quarter 2026 Financial Results Conference Call on Thursday, November 13, 2025 at 8:30 a.m. Eastern Time
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a leader in the development and commercialization of productivity solutions designed to...
Bioceres downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Bioceres (BIOX) to Perform from Outperform without a price target The firm believes the company’s portfolio recapitalization “now appears incrementally challenging.” Bioceres is...
Bioceres, Colorado Wheat Research Foundation team on HB4 wheat commercialization
Bioceres (BIOX) and the Colorado Wheat Research Foundation announced a strategic collaboration to jointly develop and commercialize HB4 wheat in the United States. The agreement combines Bioceres’ pro...
Bioceres Crop Solutions and Colorado Wheat Research Foundation Partner to Advance Climate-Resilient HB4® Wheat in the U.S.
ROSARIO, Argentina & FORT COLLINS, Colorado--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) and the Colorado Wheat Research Foundation (CWRF) today announced a strategic collaboration t...
Bioceres price target lowered to $5 from $8 at Lake Street
Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below…
Bioceres downgraded to Hold from Buy at Canaccord
Canaccord downgraded Bioceres (BIOX) to Hold from Buy with a price target of $2.50, down from $6.50. The company’s sales and adjusted EBITDA loss in fiscal Q4 were lower than…
Bioceres Crop Solutions Earnings Call Transcript: Q4 2025
Fiscal 2025 saw a 28% revenue decline and margin compression due to macroeconomic headwinds in Argentina and a strategic shift in the seed business. Cost controls, working capital improvements, and international growth in core technologies are expected to support recovery and margin expansion as the company transitions to a more scalable model.
Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2025 Financial and Operational Results
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricul...
Bioceres Crop Solutions to Host Fiscal Fourth Quarter and Full Year 2025 Financial Results Conference Call on Tuesday, September 9, 2025 at 8:30 a.m. Eastern Time
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a leader in the development and commercialization of productivity solutions designed to...
Bioceres CFO Lopez Lecube steps down
In a regulatory filing yesterday, Bioceres (BIOX) Crop Solutions disclosed that the board of directors and Enrique Lopez Lecube, Chief Financial Officer, agreed to initiate a transition in the company...
Bioceres downgraded to Hold from Buy at Brookline
Brookline downgraded Bioceres (BIOX) to Hold from Buy with a $26 price target The firm views the timing of the CFO’s departure as concerning.
Bioceres Crop Solutions Announces Changes to Board of Directors
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate ag...
Bioceres Crop Solutions Earnings Call Transcript: Q3 2025
Q3 saw a $40M year-over-year cash flow improvement despite lower revenues, driven by strategic seed business changes and working capital efficiency. RinoTec’s EPA approval and organizational restructuring position the company for growth, with positive outlooks in key markets.
Bioceres reports Q3 revenue $60.6M, consensus $61.87M
Federico Trucco, Bioceres (BIOX)’ CEO, commented: “Our third fiscal quarter is typically uneventful, as it falls in the off-season for most of our geographies. This year, however, it stands out…